secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001104659-26-042886
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences appoints Glenn Reicin as CFO; reaffirms 2026 revenue guidance of $1.0-$1.04B
--------------------------------------------------------------------------------

- Sandip Kapadia steps down as CFO effective April 14, 2026 to pursue other career opportunities.
- Glenn Reicin appointed CFO; previously CFO at Eccogene and Alladapt, Managing Director at Skyline Ventures.
- New CFO: $500K base salary, 50% target bonus, $3M option grant vesting over four years.
- Company reiterates 2026 net product revenue guidance of $1.0-$1.04 billion from WAKIX sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926042886/0001104659-26-042886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926042886/hrmy-20260414x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-042886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer